NLS PHARMACEUTICS AG Aktie

Following NASDAQ approval, NLS Pharmaceutics and Kadimastem completed the merger as planned on October 30; the combined company will operate as NewcelX and is expected to trade under the ticker NCEL from October 31. After the transaction, Kadimastem shareholders will hold approximately 84.4% of the new company and NLS shareholders about 15.6%; each Kadimastem share will be exchanged for roughly 0.62 NLS shares on a post‑split basis. NewcelX intends to continue Kadimastem’s clinical programs, including AstroRx (phase‑2a in ALS) and IsletRx for insulin‑dependent diabetes; the company currently reports negative EBITDA but has received a "FAIR" financial rating. » Altro su de.investing.com

NLS Pharmaceutics’ stock fell about 20.4% after shareholders approved the merger with Israeli cell‑therapy company Kadimastem. Upon closing, the combined company will be listed on the NASDAQ as NewCelX under the ticker NCEL; Kadimastem shareholders will hold 84.4% and NLS shareholders 15.6% of the new company. The merger combines Kadimastem’s cell‑therapy pipeline (including AstroRx for ALS and IsletRx for diabetes) with NLS’s CNS expertise; Ronen Twito will be CEO and Prof. Michel Revel chief scientific officer. Shareholders also approved a par‑value reduction, a reverse split, a capital increase and the election of a new board of directors. » Altro su de.investing.com

Shareholders of NLS Pharmaceutics voted at an extraordinary general meeting to approve the merger with Kadimastem, clearing the final corporate-law hurdle for the transaction. The combined company will be called NewCelX and, pending Nasdaq approval, is expected to trade under the ticker NCEL; Kadimastem shareholders will hold 84.4% and NLS shareholders 15.6%. Leadership positions have been assigned: Ronen Twito will serve as executive chairman and CEO, and Prof. Michel Revel as chief scientific officer. The merger brings together Kadimastem’s cell therapy programs (including AstroRx phase‑2a for ALS and IsletRx for diabetes) with NLS’s expertise in small-molecule drugs; the SEC has approved the registration and Kadimastem received an IsletRx patent in Hong Kong. » Altro su de.investing.com